Pfenex Inc
Change company Symbol lookup
Select an option...
PFNX Pfenex Inc
BAC Bank of America Corp
DLTR Dollar Tree Inc
SOLCF SOL Global Investments Corp
MLTI Credit Suisse X-Links Multi-Asset High Income ETN
JPM-E JPMorgan Chase & Co
BSET Bassett Furniture Industries Inc
INDB Independent Bank Corp
CPHI China Pharma Holdings Inc
DRWB Laurel Road Bank
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Closing Price
$3.93
Day's Change
-0.07 (-1.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.23
Day's Low
3.92
Volume
(Below Average)
Volume:
53,537

10-day average volume:
61,420
53,537

Company Profile

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
4.20x
Price/Book (MRQ)
1.84x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

December 2018
Current Month
694.5K
Previous Month
736.0K
Percent of Float
2.43%
Days to Cover
5.2754 Days

Share Information

PFNX is in a share class of common stock
Float
28.5M
Shares Outstanding
31.5M
Institutions Holding Shares
96
76.64%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Jason Grenfell-GardnerChmn.
  • Evert B. SchimmelpenninkPres.
  • Susan A. KnudsonCFO
  • Shawn A. ScrantonCOO
  • Patricia LadyCAO

Address

Insider Trading

During the most recent quarter, 26K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by , Copyright © 2019. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.